2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 510

Lipid Profile and Cardiovascular Risk in Subjects at Risk for Rheumatoid Arthritis
Abstract Number: 511

Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis
Abstract Number: 512

Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Abstract Number: 513

Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
Abstract Number: 514

Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
Abstract Number: 515

How Knowledgeable Are Patients with Rheumatoid Arthritis about Cardiovascular Disease?
Abstract Number: 516

Microalbuminuria in Rheumatoid Arthritis: Investigating the Association with Diffuse Functional and Morphological Alterations of the Retinal Microvasculature, the Dermal Capillary Network and the Coronary Microcirculation
Abstract Number: 517

Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases
Abstract Number: 518

Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis
Abstract Number: 519

Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
Abstract Number: 520

Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program
Abstract Number: 521

The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment
Abstract Number: 522

Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis
Abstract Number: 523

The Prevalence and Clinical Characteristics of Rheumatoid Arthritis with Interstitial Lung Disease in the San Joaquin Valley of Central California
Abstract Number: 524

Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].